Europe Antibody Drug Conjugates Market Strategies, Top Players, Growth Opportunities, Analysis and Forecast by 2031

The Europe Antibody Drug Conjugates Market size is expected to reach US$ 9,598.7 Million by 2031 from US$ 1,990.5 Million in 2023. The market is estimated to record a CAGR of 21.7% from 2023 to 2031.

Executive Summary and Europe Antibody Drug Conjugates Market Analysis:

The Europe antibody-drug conjugate market is segmented into the UK, Germany, France, Italy, Spain, and the Rest of Europe. In December 2022, Daiichi Sankyo and AstraZeneca's ENHERTU (trastuzumab deruxtecan) were recommended for approval in the European Union (EU) as a standalone treatment for adult patients with unresectable or metastatic HER2 low (IHC 1+ or IHC 2+/ISH-) breast cancer. This recommendation applies to patients who have previously received chemotherapy for a metastatic condition or who have experienced disease recurrence during or within 6 months of completing adjuvant chemotherapy. Therefore, increasing investments by governments in the EU and developments by the market players are propelling the antibody-drug conjugates market growth in the region.

Europe Antibody Drug Conjugates Market: Strategic Insights

Europe Antibody Drug Conjugates Market Segmentation Analysis:

• By Technology, the Europe Antibody Drug Conjugates Market is segmented into Cleavable Linker and Non-cleavable Linker. Cleavable Linker held the largest share of the market in 2023.
• By Application, the Europe Antibody Drug Conjugates Market is segmented into Blood Cancer, Brain Cancer, Breast Cancer, Ovarian Cancer, Lung Cancer, and Others. Breast Cancer held the largest share of the market in 2023.
• By Target, the Europe Antibody Drug Conjugates Market is segmented into HER2, CD22, CD30, and Others. HER2 held the largest share of the market in 2023.
• By Distribution Channel, the Europe Antibody Drug Conjugates Market is segmented into Retail Pharmacies, Hospital Pharmacies, and Online Pharmacies. Hospital Pharmacies held the largest share of the market in 2023.

Europe Antibody Drug Conjugates Market Players Density: Understanding Its Impact on Business Dynamics

The Europe Antibody Drug Conjugates Market is growing rapidly, driven by increasing end-user demand due to factors such as evolving consumer preferences, technological advancements, and greater awareness of the product's benefits. As demand rises, businesses are expanding their offerings, innovating to meet consumer needs, and capitalizing on emerging trends, which further fuels market growth.

Europe Antibody Drug Conjugates Market Outlook

Investments in antibody-drug conjugates facilitate the discovery of new therapeutic targets and accelerate the development of innovative antibody-drug conjugates that have greater effectiveness and fewer side effects than traditional therapies. The approval of new products enhances treatment options for patients, particularly in oncology, where antibody-drug conjugates are increasingly recognized for delivering cytotoxic agents directly to cancer cells, minimizing damage to healthy tissues.
Further, the extension of indications approved for existing antibody-drug conjugates has also contributed significantly to market growth. As more indications are approved, the potential patient population for these therapies increases, leading to higher sales and market penetration. Moreover, this trend boosts the market size and encourages further research and development by creating a positive feedback loop that fosters innovation and approval of new products. In October 2023, Daiichi Sankyo and Merck & Co., Inc. entered into a global development and commercialization agreement for three of Daiichi Sankyo's DXd antibody-drug conjugate (antibody-drug conjugate) candidates: patritumab deruxtecan (HER3-DXd), ifinatamab deruxtecan (I-DXd), and raludotatug deruxtecan (R-DXd). The companies will jointly develop and potentially commercialize these antibody-drug conjugate candidates worldwide, except in Japan, where Daiichi Sankyo will maintain exclusive rights. Daiichi Sankyo will be solely responsible for manufacturing and supply.

The regulatory landscape has also evolved to support the faster approval of antibody-drug conjugates. Regulatory agencies are increasingly recognizing the unique benefits of these therapies, which has led to streamlined approval processes for promising candidates. This shift is crucial in a market where time-to-market can significantly impact a product's commercial success. Thus, the increased availability of approved antibody-drug conjugates with significant investments in research and development, the expansion of approved indications, supportive regulatory frameworks, and a rising demand for targeted biologic therapies is a to the growth of the market.

Europe Antibody Drug Conjugates Market Country Insights

By country, the Europe Antibody Drug Conjugates Market is segmented into the United Kingdom, Germany, France, Italy, Spain, and the Rest of Europe. Germany held the largest share in 2023.

German companies have shown significant interest in developing antibody-drug conjugates. German-based biopharmaceutical leaders highly focus on expanding their production capacity outside the country and enhancing the market size. In September 2020, Merck KGaA announced the expansion of its high-potency active pharmaceutical ingredient (HPAPI) and antibody-drug conjugates production capacity and capabilities in the US, with a total valuation of US$ 62 million (€59 million). The manufacturing center was scheduled for completion in mid-2022 and was functioning from 2021, creating more than 50 full-time jobs. The expansion would allow the large-scale production of potentially potent compound therapies to treat cancer.

Europe Antibody Drug Conjugates Market Company Profiles

Some of the key players operating in the market include GSK Plc, F. Hoffmann-La Roche Ltd, Pfizer Inc, Bristol-Myers Squibb Co, Johnson & Johnson, Takeda Pharmaceutical Co Ltd, AstraZeneca Plc, Astellas Pharma Inc, AbbVie Inc, Merck KGaA, Gilead Sciences Inc, BioNTech SE, Daiichi Sankyo Co Ltd, RemeGen Co Ltd, and ADC Therapeutics SA.

These players are adopting various strategies such as expansion, product innovation, and mergers and acquisitions to provide innovative products to their consumers and increase their market share.

Europe Antibody Drug Conjugates Market Research Methodology

The following methodology has been followed for the collection and analysis of data presented in this report:

Secondary Research

The research process begins with comprehensive secondary research, utilizing internal and external sources to gather qualitative and quantitative data for each market. Commonly referenced secondary research sources include, but are not limited to:

• Company websites, annual reports, financial statements, broker analyses, and investor presentations
• Industry trade journals and other relevant publications
• Government documents, statistical databases, and market reports
• News articles, press releases, and webcasts specific to companies operating in the market

Note:

Primary Research

The Insight Partners conducts a significant number of primary interviews each year with industry stakeholders and experts to validate its data analysis and gain valuable insights. These research interviews are designed to:

• Validate and refine findings from secondary research
• Enhance the expertise and market understanding of the analysis team
• Gain insights into market size, trends, growth patterns, competitive dynamics, and future prospects

Primary research is conducted via email interactions and telephone interviews, encompassing various markets, categories, segments, and sub-segments across different regions. Participants typically include:

• Industry stakeholders: Vice Presidents, Business Development Managers, Market Intelligence Managers, and National Sales Managers
• External experts: Valuation specialists, research analysts, and key opinion leaders with industry-specific expertise